• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment.

作者信息

Dickhoff Chris, Heineman David Jonathan, Bahce Idris, Senan Suresh

机构信息

Department of Cardiothoracic Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.

Department of Cardiothoracic Surgery, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, The Netherlands.

出版信息

J Thorac Oncol. 2023 Sep;18(9):1124-1128. doi: 10.1016/j.jtho.2023.06.002.

DOI:10.1016/j.jtho.2023.06.002
PMID:37599045
Abstract
摘要

相似文献

1
Unresectable Stage III NSCLC Can Be Reevaluated for Resectability After Initial Treatment.不可切除的 III 期非小细胞肺癌在初始治疗后可重新评估其可切除性。
J Thorac Oncol. 2023 Sep;18(9):1124-1128. doi: 10.1016/j.jtho.2023.06.002.
2
Phase II study of neoadjuvant chemotherapy in patients with surgically-proven, unresectable stage III non-small cell lung cancer.经手术证实为不可切除的 III 期非小细胞肺癌患者新辅助化疗的 II 期研究。
Anticancer Res. 2002 Nov-Dec;22(6B):3519-24.
3
The role of neoadjuvant chemotherapy in marginally resectable or unresectable stage III non-small cell lung cancer.新辅助化疗在可切除边缘或不可切除的 III 期非小细胞肺癌中的作用。
Neoplasma. 2002;49(3):189-96.
4
["A priori" resectability of NSCLC pulmonary neoplasms in relation to the new international classification].非小细胞肺癌肺部肿瘤的“术前”可切除性与新国际分类的关系
Rev Med Liege. 1995 Jun;50(6):264-7.
5
Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging.ⅢA期N2非小细胞肺癌患者的多模式治疗。术前化疗对可切除性和降期的影响。
J Thorac Cardiovasc Surg. 1993 Oct;106(4):696-702.
6
FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.18F-氟代脱氧葡萄糖正电子发射断层显像/X线计算机体层成像用于评估新辅助治疗后N2期非小细胞肺癌患者的可切除性。
Ann Nucl Med. 2016 Feb;30(2):114-21. doi: 10.1007/s12149-015-1038-7. Epub 2015 Nov 27.
7
Surgical treatment of stage III non-small cell lung cancer.III期非小细胞肺癌的外科治疗
Lung Cancer. 2001 Dec;34 Suppl 2:S137-43. doi: 10.1016/s0169-5002(01)00358-0.
8
Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response.对于IIB期（肺上沟T3N0）/III期非小细胞肺癌，顺铂/依托泊苷同步化疗加三维适形放疗后行手术，可产生较高的病理完全缓解率。
Eur J Cardiothorac Surg. 2008 May;33(5):829-36. doi: 10.1016/j.ejcts.2008.01.063. Epub 2008 Mar 25.
9
Surgery for advanced stage lung cancer.晚期肺癌手术
Semin Surg Oncol. 2000 Mar;18(2):137-42. doi: 10.1002/(sici)1098-2388(200003)18:2<137::aid-ssu7>3.0.co;2-a.
10
[Guideline on 'non-small cell lung carcinoma; staging and treatment'].['非小细胞肺癌；分期与治疗指南']
Ned Tijdschr Geneeskd. 2005 Jan 8;149(2):72-7.

引用本文的文献

1
Surgery for Patients With cT3/4N2M0, Stage IIIB NSCLC. Is It Time to Redefine Resectability?cT3/4N2M0 ⅢB 期非小细胞肺癌患者的手术治疗。是时候重新定义可切除性了吗？
JTO Clin Res Rep. 2024 Nov 14;6(1):100766. doi: 10.1016/j.jtocrr.2024.100766. eCollection 2025 Jan.
2
Stage III NSCLC treatment options: too many choices.III期非小细胞肺癌的治疗选择：选择过多。
Breathe (Sheff). 2024 Oct 1;20(3):240047. doi: 10.1183/20734735.0047-2024. eCollection 2024 Oct.
3
Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II-III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study.
新辅助卡瑞利珠单抗（一种抗程序性死亡蛋白1抗体）联合化疗或阿帕替尼（一种血管内皮生长因子受体2抑制剂）用于初始不可切除的II-III期非小细胞肺癌：一项多中心、双臂、2期探索性研究。
Signal Transduct Target Ther. 2024 Jun 14;9(1):145. doi: 10.1038/s41392-024-01861-w.
4
Contemporary Strategies: Incorporating Immunotherapy into Stage 3 Non-small Cell Lung Cancer Treatment.当代策略：将免疫疗法纳入Ⅲ期非小细胞肺癌治疗
Tuberc Respir Dis (Seoul). 2024 Jul;87(3):292-301. doi: 10.4046/trd.2023.0162. Epub 2024 Mar 28.
5
The Impact of Immunotherapy Use in Stage IIIA (T1-2N2) NSCLC: A Nationwide Analysis.免疫疗法在IIIA期（T1-2N2）非小细胞肺癌中的应用影响：一项全国性分析。
JTO Clin Res Rep. 2024 Feb 20;5(3):100654. doi: 10.1016/j.jtocrr.2024.100654. eCollection 2024 Mar.
6
Resection of the Primary Tumor and Survival in Patients with Single-Site Synchronous Oligometastatic Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Database.单一部位同步寡转移非小细胞肺癌患者的原发肿瘤切除术与生存：国家癌症数据库的倾向性匹配分析。
J Am Coll Surg. 2024 Jun 1;238(6):1122-1136. doi: 10.1097/XCS.0000000000001035. Epub 2024 Feb 9.